PTC Therapeutics (PTCT) said Friday that its marketing authorization application for Sephience for the treatment of phenylketonuria has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.
The CHMP opinion recommends a label that includes all ages and disease severities, the company said, adding it expects the European Commission to take a decision in about two months.
The company said launch planning in Europe is ongoing, with Germany as a priority market.
Sephience, or sepiapterin, is also under review in the US for phenylketonuria, an inherited metabolic disease that affects the brain, PTC said.
Price: 48.78, Change: -0.77, Percent Change: -1.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.